Terms ending in 2039
Every in-force patent on ImmunoGen, Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,274,121 | Methods for Antibody Drug Conjugation, Purification, and Formulation In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 11,793,885 | SUBSTITUTED BENZO[5,6][1,4]DIAZEPINO[1,2-a]INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 10,851,117 | Methods of Preparing Cytotoxic Benzodiazepine Derivatives In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 10,913,713 | Methods of Preparing Cytotoxic Benzodiazepine Derivatives In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 11,981,688 | Methods of Preparing Cytotoxic Benzodiazepine Derivatives In force · Medium confidence | ImmunoGen, Inc. | In force | Medium confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.